About NGX Bio
NGX Bio is a company based in San Francisco (United States) founded in 2014. It operates as a B2B. NGX Bio has raised $3.68 million across 3 funding rounds from investors including 180 Degree Capital, Third Kind Venture Capital and Band of Angels. NGX Bio operates in a competitive market with competitors including Novogene Corporation, Rejuvenate Bio, Source BioScience, Macrogen and Beikang Medical, among others.
- Headquarter San Francisco, United States
- SectorsHealthcare
- Website ngxbio.com
- Social X Facebook
- Legal Name Ngx Bio
- Total Equity Funding$3.68M (USD)
in 3 rounds
- Latest Funding Round$3M (USD), Series A
Aug 2017
- Investors180 Degree Capital
& 4 more
Funding Insights of NGX Bio
NGX Bio has successfully raised a total of $3.68M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $3 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.68M
- Total Rounds 3
- Last Round Series A — $3M
- First Round $375,000
(Mar 2015)
- Investors Count 5
All 3 funding rounds of NGX Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2017 | $3M | Series A | – | 180 Degree Capital | |
| Sep 2015 | $300,000 | Seed | – | – | – |
| Mar 2015 | $375,000 | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in NGX Bio
NGX Bio has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include 180 Degree Capital, Third Kind Venture Capital and Band of Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
Early-stage investments in finance and financial services are targeted. | – | 3kvc.com | New York, United States | |
Angel investing in high-tech and life science startups since 1994. | – | bandangels.com | - | |
An angel investor network is formed by UC Berkeley affiliates. | 2012 | berkeleyangelnetwork.com | San Francisco, United States | |
Venture capital fund focused on multiple sectors | – | lateralcapital.com | Sarasota, United States |
Investor details for NGX Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NGX Bio
3 dated milestones of NGX Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded NGX Bio is founded.
- Funding First funding round of $375K.
- Funding Latest funding round, Series A, of $3.0M.
Competitors of NGX Bio
NGX Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novogene Corporation, Rejuvenate Bio, Source BioScience, Macrogen and Beikang Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| rejuvenatebio.com | 2017 | San Diego, United States | $14.58M | 39 | Gene-editing platform and anti-aging therapy for dogs are developed. | |
| sourcebioscience.com | 1903 | Nottingham, United Kingdom | – | 273 | Multiple genomic services are provided for analysis and diagnostics. | |
| macrogen.com | 1997 | Seoul, South Korea | – | – | Next-generation sequencing and genomics services are provided globally. | |
| basecare.cn | 2010 | Suzhou, China | $36.52M | – | NGS-based diagnostic solutions for neonatal screening are developed. | |
| decode.com | 1996 | Reykjavik, Iceland | – | – | Bioinformatics platform for genetic disease analysis is provided. | |
| mgrc.com.my | 2004 | Kuala Lumpur, Malaysia | – | – | Genome sequencing, analysis, and genetic screening services are provided. | |
| enarabio.com | 2016 | Oxford, United Kingdom | $84.05M | 38 | T-cell interfaces for cancer therapeutics are developed. | |
| genewiz.com | 1999 | South Plainfield, United States | – | 452 | Genomic services are provided for the life sciences industry. | |
| 20n.com | 2013 | San Francisco, United States | $2.22M | – | Computational tools are developed to engineer microbes for synthetic biology. |
Detailed competitors of NGX Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to NGX Bio
10 companies that operate in the same segment as NGX Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NGX Bio
NGX Bio was founded in 2014 and raised its 1st funding round 1 year after it was founded.
NGX Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
NGX Bio is a funded company, having raised a total of $3.68M across 3 funding rounds to date. The company's 1st funding round was a Seed of $375K, raised on Mar 2015.
NGX Bio operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, focusing on genomic solutions, and service provision. Delivers genomics services for advanced biological research and applications. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
NGX Bio's top competitors include Novogene Corporation, Source BioScience and Genewiz.
NGX Bio has 5 investors. Key investors include 180 Degree Capital, Third Kind Venture Capital, Band of Angels, Berkeley Angel Network, and Lateral Capital.
NGX Bio operates through Ngx Bio.